rivenprost
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2006 (NCT00296556)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Prostanoid EP4 receptorAGONIST
PTGER4 agonist
Chemistry & pharmacology
Loading structure…
SMILES
COCc1cccc(C[C@H](O)/C=C/[C@H]2[C@H](O)CC(=O)[C@@H]2CCSCCCC(=O)OC)c1- Mol. weight
- 450.6 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL303960 ↗
Also known as
- ae1 734
- ae1-734
- methyl 7-((1r,2r,3r)-3-hydroxy-2-((e)-(3s)-3-hydroxy-4-(m-methoxymethylphenyl)-1-butenyl)-5-oxocyclopentyl)-5-thiaheptanoate
- ono4819
- ono-4819
- ono-4819
- ono-4819
- ono-ae1-734
- rivenprost
- rivenprost
- rivenprost
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00296556 | Phase 2 | Feb 1, 2006 | Kyoto University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kyoto University | Academic/Hospital | 1 | 1 | 1 | 2006 |
1 organizations
Page 1 / 1